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Abstract
Prostanoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Prostanoid Receptors
[644]) are activated by the endogenous ligands prostaglandins PGD2, PGE1, PGE2 , PGF2α, PGH2, prostacyclin
[PGI2] and thromboxane A2. Measurement of the potency of PGI2 and thromboxane A2 is hampered by their
instability in physiological salt solution; they are often replaced by cicaprost and U46619, respectively, in
receptor characterization studies.
Contents
This is a citation summary for Prostanoid receptors in the Guide to Pharmacology database (GtoPdb). It exists
purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation
analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here
under database links.
GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a
reference work which is most usefully represented as an on-line database. As in any publication this work
should be appropriately cited, and the papers it cites should also be recognized. This document provides a
citation for the relevant parts of the database, and also provides a reference list for the research cited by those
parts.
Please note that the database version for the citations given in GtoPdb are to the most recent preceding version
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in which the family or its subfamilies and targets were substantially changed. The links below are to the current
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